|
Malimon V.V., Kokorin V.A.
New opportunities for chronic heart failure patients’ treatment: Focus at dapagliflosin
|
№4 / 2023
|
|
Pyrikova N.V., Mozgunov N.A., Osipov I.V.
Results of a 12-month telemonitoring of chronic heart failure patients after hospitalization with its decompensation
|
№4 / 2023
|
|
Shutov A.M., Efremova E.V., Serov V.A.
Blockade of renin-angiotensin-aldosterone system in patients with chronic heart failure and chronic kidney disease
|
№3 / 2023
|
|
Panevin T.S., Eliseev M.S., Bobkova A.O., Dimitreva A.E., Urumova M.M.
Use of dapagliflozin in a comorbid patient: new opportunities
|
№3 / 2023
|
|
Kravchenko A.Ya., Budnevsky A.V., Chernik T.A., Tokmachev R.E.
Soluble suppression of tumorigenicity 2 (sST2) as a predictor of adverse outcomes of chronic heart failure
|
№1 / 2023
|
|
Larina V.N., Lunev V.I.
Bendopnea and global left ventricular function index as possible factors for prediction of mortality in patients with chronic heart failure
|
№9 / 2022
|
|
Karoli N.A., Borodkin A.V., Rebrov A.P.
Risk factors for the development of adverse outcomes in patients with chronic obstructive pulmonary disease
|
№5 / 2022
|
|
Kravchenko A.Ya., Chernik T.A., Tokmachev R.E.
Soluble suppression of tumorigenicity 2 (sST2) in chronic heart failure
|
№4 (приложение) / 2022
|
|
Efremova L.S., Vasilyeva L.V.
Relationship of aldosterone and tissue inhibitor of matrix metalloproteinase-1 in the pathogenesis of chronic heart failure with a moderately reduced ejection fraction in patients with diabetes mellitus
|
№4 (приложение) / 2022
|
|
Budnevsky A.V., Kravchenko A.Ya., Tokmachev R.E. Chernik T.A.
Impact of physical rehabilitation on the course of chronic heart failure
|
№4 (приложение) / 2022
|
|
Shishkova V.N., Ustarbekova D.B., Shishkov V.A., Imamgayazova K.E., Kapustina L.A.
Psycho-emotional disorders in chronic heart failure patients
|
№1 / 2022
|
|
Bolieva L.Z., Adasheva T.V., Malyavin A.G., Bichenova E.R., Daurova M.D.
Obstructive sleep apnea and chronic heart failure
|
№1 / 2022
|
Русский
